The AMA has collected more than 400 educational and other resources to provide evidence-based recommendations for physicians and policymakers.
This module describes the history of methadone maintenance and the effectiveness and key myths of opioid agonist treatment, explores empathizing with patients taking methadone or buprenorphine, and empowers clinicians to support patients and their significant others.
A Joint Statement by the American Correctional Association (ACA) and ASAM support the use of evidence-based practices for the treatment of opioid use disorders for individuals within the criminal justice system.
Given the complex needs of pregnant and postpartum women and their children, and the number of systems they encounter during critically important periods in their lives, ASAM provides policy recommendations on substance use, misuse, and SUDs during and following pregnancy.
ASAM developed the National Practice Guideline to provide information on evidence-based treatment of opioid use disorder, and is the first to address all of the FDA-approved medications available to treat addiction involving opioid use and opioid overdose in a single document
This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. ASAM also provides the additional 16 hours that are required for NPs and PAs
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018.
The AMA Substance Use and Pain Care Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s drug overdose epidemic—and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.Learn More